Equities research analysts forecast that Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) will report earnings per share of ($0.68) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.77). Jounce Therapeutics reported earnings per share of ($0.08) during the same quarter last year, which suggests a negative year-over-year growth rate of 750%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Jounce Therapeutics will report full-year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.92) to ($1.72). For the next year, analysts anticipate that the company will post earnings of ($2.26) per share, with EPS estimates ranging from ($3.27) to ($1.38). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.15). During the same period in the previous year, the business earned ($0.58) EPS.
A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in Jounce Therapeutics by 310.1% in the third quarter. Goldman Sachs Group Inc. now owns 673,926 shares of the company’s stock valued at $5,007,000 after buying an additional 509,577 shares during the period. Panagora Asset Management Inc. lifted its stake in Jounce Therapeutics by 7.0% in the fourth quarter. Panagora Asset Management Inc. now owns 113,065 shares of the company’s stock valued at $944,000 after buying an additional 7,369 shares during the period. GSA Capital Partners LLP lifted its stake in Jounce Therapeutics by 84.1% in the third quarter. GSA Capital Partners LLP now owns 96,900 shares of the company’s stock valued at $720,000 after buying an additional 44,277 shares during the period. AXA S.A. lifted its stake in Jounce Therapeutics by 77.2% in the third quarter. AXA S.A. now owns 35,800 shares of the company’s stock valued at $266,000 after buying an additional 15,600 shares during the period. Finally, BlackRock Inc. lifted its stake in Jounce Therapeutics by 3.2% in the third quarter. BlackRock Inc. now owns 2,534,851 shares of the company’s stock valued at $18,834,000 after buying an additional 77,752 shares during the period. Institutional investors and hedge funds own 78.20% of the company’s stock.
Shares of JNCE traded up $0.17 during midday trading on Friday, hitting $4.69. 162,296 shares of the stock traded hands, compared to its average volume of 369,425. Jounce Therapeutics has a 1-year low of $4.06 and a 1-year high of $9.81. The business’s 50 day moving average price is $6.20 and its two-hundred day moving average price is $7.14. The firm has a market capitalization of $242.35 million, a PE ratio of -2.37 and a beta of 1.12.
Jounce Therapeutics Company Profile (Get Rating)
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.
- Get a free copy of the StockNews.com research report on Jounce Therapeutics (JNCE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.